Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zenabis Global Inc. T.ZENA

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
We are a diverse, passionate team of doctors, scientists, researchers, growers, educators, and advocates who came together with the goal of increasing access to safe, high quality cannabis for medical patients and recreational consumers. Our four facilities are located coast-to-coast across Canada in Delta and Langley, British Columbia; Atholville, New Brunswick; and Stellarton, Nova Scotia. Zenabis currently owns 3.5 million square feet of facility space.


TSX:ZENA - Post by User

Zenabis Global Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Post by buddyboybruceon Oct 19, 2020 7:14pm
145 Views
Post# 31745575

Zenabis War Room - winning the battle on debt

Zenabis War Room - winning the battle on debt
Zenabis paid down some 2021 debt already from the September/2020 Offering because they knew they would be pushing today's press release convertible note debt to next year. They also know that the sale of Delta is immenent and that cannabis earnings are now allowing Zenabis to methodically whittle down debt going forward. Zenabis will not need to raise incremental capital going forward as they've secured a beachhead and multiple Cannabis 2.0 revenue streams will act to advance debt retirement. 

Zenabis used a large portion of the proceeds from the June/2020 and September/2020 public equity offerings to pay down $20.8 million in debt across multiple tranches. Through this deleveraging, Zenabis reduced its financial risk by decreasing near-term debt repayments and reducing its total interest expense. Zenabis' post-offering capital structure is outlined below: 
https://www.zenabis.com/wp-content/uploads/slider/zenabis-presentation_2020-08-31_04_30_25/zenabis-investor-presentation-25-sept-2020-v4-ohh-updates-16.jpg
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities